Imperial Blue lifts Tilaknagar revenue 165%, but PAT falls 64% to ₹32 Cr on integration costs
PAT -64.3% YoY · revenue +165.4% · margins compressing
₹2,252.42 Cr
+165.4% YoY
₹31.59 Cr
-64.3% YoY
1.4%
-8.8pp YoY
₹1.28
Tilaknagar Industries' first full quarter with the acquired Imperial Blue (IB) business transformed its scale but not yet its profit. Consolidated revenue from operations rose ~165% YoY to ₹2,252 Cr (net of ₹1,206 Cr excise duty, ~₹1,046 Cr), driven entirely by the IB division bought from Pernod Ricard for ₹3,442 Cr (completed Dec 2025). Consolidated PAT, however, fell to ₹31.6 Cr from ₹88.5 Cr a year ago — down ~64% reported, and still down ~30% even after excluding the ₹30.1 Cr exceptional charge for IB integration and transition costs. So the revenue explosion is inorganic and the bottom line went backwards on a like-for-like basis.
Q1 FY-2027 vs prior quarters
The margin bridge explains the gap. Operating EBITDA of ~₹173 Cr translates to roughly 16% of net revenue — landing at the lower end of the 16–18% band management/brokerages have guided for FY27, consistent with the "margins near the low end" framing given near-term raw-material inflation. Below EBITDA, two acquisition-driven lines crush the print: finance costs jumped to ₹66.4 Cr (from ₹2.8 Cr a year ago) on the debt funding the deal, and depreciation rose to ₹45.5 Cr (from ₹7.3 Cr). Tax expense was nil. The result is a profit that is thin relative to the enlarged asset and debt base — the classic shape of an integration year.
The stock went into the print at ₹446.7, up 2.4% over the past month of trading.
What the summary numbers don't show
Standalone PAT ₹33.3 Cr on revenue ₹2,252 Cr (EPS ₹1.35) — broadly in line with consolidated
Management guides for high-single to low-double digit volume growth for the combined business in FY27, accelerating to low-double digit growth in subsequent years, with revenue growing 150-200 bps above volume. They project a consolidated EBITDA margin expansion of 150-250 bps over the next 24-36 months, driven by sign
— This quarter: met
Sequentially the quarter reads better: revenue grew ~8% QoQ and the company swung back to a ₹31.6 Cr profit from a ₹14.9 Cr consolidated loss in Q4 FY26, when exceptional costs peaked. Operationally momentum is real — June 2026 saw a record 3.4 million cases and IB crossed 2 million cases in both May and June — which supports management's high-single to low-double-digit FY27 volume guide. Concurrent board actions this quarter fit the integration theme: approval of a composite amalgamation of two wholly-owned subsidiaries (Punjabexpo Breweries, Vahni Distilleries; appointed date 1 Apr 2026, pending NCLT), incorporation of a Nigeria WOS, and the addition of an independent director. No published Q1 street consensus was found, so the print is best judged against guidance rather than a number: margins met the low end, volumes are tracking, but reported profitability remains suppressed until integration costs roll off and the ₹3,442 Cr acquisition debt is worked down (management targets net debt/EBITDA below 1.0x by FY29). The auditor's qualified conclusion on the un-assessed ENA-plant impairment is an outstanding governance flag, not a P&L event this quarter.
W1
Roll-off of the ₹30.1 Cr/quarter IB integration exceptional — the point at which underlying PAT (₹61.7 Cr pre-exceptional this quarter) becomes the headline number
W2
EBITDA margin trajectory: ~16% of net revenue now vs the 16–18% guided band and management's promised 150–250 bps expansion over 24–36 months
W3
Deleveraging path: ₹66 Cr quarterly finance cost from the ₹3,442 Cr acquisition debt, against the guided net-debt/EBITDA below 1.0x by FY29
W4
Volume run-rate holding above the 3.4 million-cases June record to validate the high-single/low-double-digit FY27 volume guide
In ₹ Lakh, converted to ₹ Cr. Consol PAT ₹31.59 Cr includes ₹0.11 Cr associate share and is after a ₹30.12 Cr exceptional (Imperial Blue integration cost); zero tax expense (nil current/deferred). Revenue grossed up by ₹1,206 Cr excise duty (net revenue ~₹1,046 Cr). Auditor gave a QUALIFIED conclusion (ENA plant impairment not assessed) plus emphasis on the pending amalgamation scheme. Q4 FY26 comparative was a loss. Standalone PAT ₹33.34 Cr vs consol ₹31.59 Cr — not materially divergent.
Volume Surge Masks Profitability Collapse
Imperial Blue integration delivered 172% volume growth and ₹2,252 Cr revenue, but PAT crashed 64% to ₹31.6 Cr. The adjusted story is better—but gross margin fell 310 bps, hinting the real challenge isn't one-time costs.
₹31.6 Cr
-64.3% YoY, NPM 1.4%
₹96 Cr
~9.4%, ex-₹30 Cr exceptions
₹2,252.4 Cr
+160.7% YoY
42.1%
-310 bps QoQ
On the headline, this looks like an acquisition success story: Imperial Blue contributing 172% volume growth, revenue up 161% YoY to ₹2,252 Cr, integration 90% done by April. But dig into the profit line and the real story emerges. Reported PAT crashed 64% to ₹31.6 Cr (NPM 1.4%), leaving investors puzzled: why would profit collapse when revenue nearly tripled? The answer is tucked inside an adjusted figure of ₹96 Cr. That ₹65 Cr gap—roughly ₹30 Cr in exceptions (TSMA state transitions, integration costs) and the rest in gross margin compression—is where the quarter's true complexity lives.
Where the ₹31.6 Cr came from
The reported PAT of ₹31.6 Cr (NPM 1.4%) trails the adjusted ₹96 Cr (9.4% margin) by ₹65 Cr. Management cites ₹30 Cr in exceptions—TSMA transitions in one state and integration-related costs—which, if reversed, would bring the organic picture closer to ₹96 Cr. But the real issue is not accounting sleight. Gross margin fell 310 basis points quarter-on-quarter to 42.1%, from 45.2% in Q4 FY26. That compression is attributable to packaging inflation (glass, inputs, geopolitical pressures), partially offset by ENA input softness. The company assumes inflation remains status quo; if it persists or escalates, margins stay under pressure regardless of exceptions.
Geopolitical tensions led to inflationary pressures across packaging inputs, particularly glass, resulting in a meaningful increase in packaging costs during the quarter.
Exceptional integration; 172% volume growth YoY
Revenue grew 160.7% YoY to ₹2,252 Cr; volumes up 172%—mix-adjusted delivery confirmed.
Supported
EBITDA margin 16.1% (adjusted 14.5% post-subsidy)
Margin calculation valid; YoY growth +79% masks QoQ compression from Q4 baseline.
Overstated
PAT adjusted ₹96 Cr, margin 9.4%
Adjusted ₹96 Cr valid; but ₹65 Cr gap to reported ₹31.6 Cr includes ₹30 Cr real costs (TSMA, integration) + ₹35 Cr margin compression.
Partially overstated
Inflationary pressures 'partly offset' by ENA softness
Gross margin fell 310 bps QoQ to 42.1%; even ex-inflation would yield 44.5%—material headwind, not minor.
Overstated
Market share gains 'in all states' post-acquisition
South seamless transition, North/East/West improving; confirmed in Q&A; no granular state ranking provided.
Supported
What changed on this call
Management raised mid-term guidance, tightening the timeline for EBITDA margin recovery. FY29 is now pegged at 16–18% EBITDA (vs. prior vague '150–250 bps expansion over 24–36 months'), with an 'upward bias'. Beyond FY27, volume growth is upgraded to mid-teens CAGR (vs. prior 'accelerating to low-double digit'), driven by new product launches in FY28 onwards. FY27 volume guidance (high single- to low double-digit) is maintained—a signal the full-year is at risk given Q1 challenges. The company also confirmed 90% of Imperial Blue integrated into Tilaknagar operations by April (manufacturing complete), with 1 state under TSMA transition by March 2027.
What the market is thinking
The stock opened down 0.58% the day the result was announced (delivery 47.7%), but recovered sharply by day 3 (+4.57%) and consolidated day 5 at +4.28% from the announcement. That recovery—a -0.58% fade reversing to +4.28% by day 5—suggests the market initially disappointed on profitability but then warmed to the volume narrative and forward guidance. At ₹465.8 (as of Aug 3, 2026), the stock sits -15.26% from its all-time high of ₹549.7, trading above its 20-day, 50-day, and 200-day moving averages (neutral trend, RSI 69.4 neutral). FII ownership trimmed 154 basis points to 16.87% (from 18.41% prior quarter), while domestic institutions added 102 bps to 5.92%, suggesting domestic buyers picking up the dip. Promoter holding remains stable at 31.71%. The increasing volume trend indicates growing retail/institutional interest as the narrative clarifies.
Volume surge 172% YoY; Imperial Blue largest deluxe whisky by volume
Integration 90% complete; market share gains confirmed all 4 regions
Forward EBITDA/volume guidance upgraded; FY29 16–18% specific and tightened
Reported PAT down 64% YoY to ₹31.6 Cr despite +161% revenue—profitability disconnect
Gross margin compression 310 bps QoQ; inflation assumption status quo (risky)
Adjusted PAT ₹96 Cr includes ₹30 Cr exceptions (TSMA, integration) = real, not transient
Competitive intensity rising (ICONiQ +50%, McDowell's); trade spend escalation risk
Telangana price increase active but not yet finalized; net debt ₹2,100 Cr, target ₹1,700 Cr by FY27-end
Profitability quality & margin sustainability
HIGHPAT -64% YoY despite +161% revenue signals cost control failure, not inflation alone. Gross margin fell 310 bps QoQ; adjusted figures mask real compression. If inflation persists, NPM stays under 2–3%, not the 9–10% adjusted metrics imply.
Integration execution—TSMA transition risk
MEDIUM1 state remains under TSMA with March 2027 outer date. Disruptions in Odisha, Punjab, Uttarakhand, Karnataka attributed to TSMA; clarity lacking. Risk of further delays or unforeseen costs.
Competitive intensity in low-prestige segment
MEDIUMICONiQ White +50% growth, McDowell's scotch push escalating. Segment dormant for years; now active. Trade spend pressure. IB's largest deluxe whisky position at risk if competitors gain share rapidly.
Debt & working capital management
MEDIUMNet debt ₹2,100 Cr Q1 (up from legacy ₹700+ Cr range); target ₹1,700 Cr by March 2027. Acquisition working capital cycle impact material. If cash generation disappoints, leverage escalates.
Forward guidance contingent on macro/policy
MEDIUMFY29 16–18% EBITDA target assumes inflation status quo, Telangana price increase (+150–200 bps margin upside), no major competitive escalation. Any of these fails, target is at risk.
New launches (FY28+) execution
LOWMid-teens volume CAGR and mid-double digit growth post-FY27 hinges on new product launches in vacant portfolio segments. Timing and market acceptance unproven.
1 · Q2 margin trajectory
Management expects Q2 margin 'similar range' to Q1 with incremental A&SP spend. Gross margin recovery from 42.1% is the critical metric. If flat or falling further, the structural headwind narrative gains traction.
2 · Telangana price increase outcome
Active government discussions ongoing (3 years since last increase). Realization adds 150–200 bps annualized margin upside. Delay or shortfall undermines Q3–Q4 seasonality expectations.
3 · Delhi relaunch progress & competitive traction
July 2026 relaunch targeting 0.5M cases within 12–18 months (pre-COVID peak). Competition from ICONiQ/McDowell's in adjacent segments will determine if ramp succeeds or faces unexpected headwinds.
Tilaknagar delivered a mixed quarter: stellar volume execution (172% YoY, Imperial Blue largest deluxe), seamless integration (90% complete), and forward guidance upgrades that are specific and tightened. But profitability deteriorated sharply—PAT -64% YoY to ₹31.6 Cr (NPM 1.4%)—due to packaging inflation, TSMA disruptions, and integration costs. Adjusted PAT of ₹96 Cr (9.4% margin) is a better lens, but gross margin compression 310 bps QoQ signals the issue isn't purely transient.
The honest read: this is strong operational execution against real operational headwinds. Near-term profitability is a trough, not a baseline. The FY29 16–18% EBITDA target and mid-teens volume CAGR are credible, but require (1) inflation moderating or price increases sticking, (2) integration completing without further disruption, and (3) competitive intensity not escalating beyond current levels. The stock's recovery from day 1 disappointment to +4.28% by day 5 suggests the market is warming to the narrative, but the -15% drawdown from ATH reflects valid execution risk.
The number to track: Gross margin trend (not just EBITDA, which aggregates many moving pieces). If it stabilizes or recovers toward 45%+ by Q3–Q4, the bull case firms. If it stays below 43%, the structural margin thesis weakens and near-term dividend pressure is real.
Record volume growth, but profitability collapsed—margin story deferred
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Maintained FY27 volume guide; upgraded mid-term growth & margin timeline. Q1 missed on margin but beat on integration—mixed track record.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Imperial Blue integration delivering on volume (172% YoY) and management executing well (90% integration done). But Q1 profitability collapsed: PAT -64% YoY to ₹31.6 Cr (NPM 1.4%), despite revenue surge, due to packaging inflation offsetting cost saves. Forward EBITDA/volume guidance upgraded (mid-teens growth, 16–18% margins by FY29), but execution risk remains: inflation status-quo assumed, competitive intensity rising, margin recovery deferred to FY29.
₹2252.4 Cr
Revenue · +160.7% YoY₹31.6 Cr
Reported PAT · −64.3% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Exceptional integration; 172% volume growth YoY
METRevenue grew 160.7% YoY to ₹2,252 Cr; volumes up 172% but mix-adjusted
EBITDA margin 16.1% (adjusted 14.5% post-subsidy)
OVERSTATEDReported EBITDA ₹169 Cr is on adjusted basis; actual margin after amortization lower
PAT adjusted ₹96 Cr, margin 9.4%
MISSReported PAT ₹31.6 Cr, NPM 1.4%—64% YoY decline. Adjusted figures exclude amortization & exceptions
Inflationary pressures 'partly offset' by ENA softness
OVERSTATEDGross margin fell 310 bps QoQ (45.2% to 42.1%); inflation impact material despite offsets
Market share gains 'in all states' post-acquisition
METConfirmed in Q&A; South seamless, North/East/West improving but no granular state data
Earnings quality
What changed since the last call
Volume growth guidance upgraded
UpgradeBeyond FY27: mid-teens CAGR (vs prior 'accelerating to low-double digit'). Driven by new launches FY28 onwards.
EBITDA margin timeline tightened
UpgradeFY29 target 16–18% with 'upward bias' (vs prior vague '150–250 bps over 24–36 months'). Concrete and front-loaded.
FY27 volume guidance maintained
NeutralHigh single- to low double-digit remains unchanged. Implication: full-year at risk given Q1 challenges.
Margin pressure acknowledged, remediation deferred
DowngradePackaging inflation ongoing; margin recovery pushed to Q3/Q4 FY27 seasonality and FY29 structural targets, not immediate.
The Q&A
Analysts pressed on state-by-state IB traction, competitive intensity in low-prestige segment (ICONiQ, McDowell's aggressiveness), margin recovery timing, and margin path for 3–4 years. Management held firm on market share gains across all regions, confident on A&SP reinvestment (28k+ outlets activated), and deferred detail on individual states. Defensive on near-term margins (inflation macro) but resolute on structural story. No major evasions.
State-wise IB traction — Abneesh Roy, Nuvama Wealth
PartialSouth seamless transition given our pre-existing scale. Karnataka good uptake post price reduction, market share improved. All states saw improvements vs exit; South better than North/East/West but all positive.
Delhi relaunch trajectory — Abneesh Roy, Nuvama Wealth
AnsweredPeak pre-COVID (2019–20) was ~0.5M cases. Target 12–18 month recovery. Team scale-up 350→850 headcount completed; pan-India sales & manufacturing footprint added.
TSMA disruption scope — Nitin Gupta, HDFC Securities
PartialIB-only, TSMA-related issues. No granular detail given on individual reasons.
Competitive intensity, low-prestige segment — Nitin Gupta, HDFC Securities
AnsweredSegment was dormant, activity now healthy for category growth. Large country liquor volume just below our price point; activations help. We adding A&SP reinvestment, 28k outlets engaged.
Margin recovery timing, inflation duration — Nitin Gupta, HDFC Securities
AnsweredAssuming inflation status quo, Q3–Q4 significant uptick due to seasonality. Q2 margin similar range but with incremental A&SP spend.
3–4 year portfolio strategy — Nitin Gupta, HDFC Securities
AnsweredFY27 focused on IB integration and distribution width. Vacant portfolio slots for new launches in next 12–36 months; mid-double digit growth, mid-teens CAGR till FY29. Premium/luxury leveraging new distribution infrastructure.
IB volume run-rate QoQ — Heer Gogri, Choice Equities
AnsweredDouble-digit growth. Acquired at 21.5M cases; expect double-digit by year-end.
IB NSR bifurcation — Heer Gogri, Choice Equities
DodgedCombined NSR only; no bifurcated segment-level NSR provided.
Telangana price increase expectations — Heer Gogri, Choice Equities
Answered3 years since last increase; active government discussions. Expected soon. 150–200 bps annualized margin upside if realized.
Prag Distillery cost synergies — Vijay Jangir, Systematix Group
Partial60–70% of bottling benefit already in Q1 numbers. Full benefit pending.
Maharashtra MML competition — Vijay Jangir, Systematix Group
AnsweredIndustry hovering 6–7 lakh cases/month, stable. IB performing well, market share gains in state at relevant price point.
Tamil Nadu market opportunity — Vaibhav Gupta, Bowhead India Fund
Answered<0.5M cases currently. TN largest brandy market (50M+ cases). Watching for policy changes post new government; imports/market-opening upside.
Execution priorities, risks, mitigation — Sucrit Patil, Eyesight Fintrade
AnsweredIntegration 90% complete by April. Near-term: widen/deepen IB distribution, A&SP reinvestment. Long-term: luxury portfolio. Risks: inflation, competition. Mitigators: price increases (Telangana, other states), supply chain optimization, cost synergies.
Financial risk management, cash flow, balance sheet — Sucrit Patil, Eyesight Fintrade
AnsweredInflation to watch. Price increases in states, ongoing discussions elsewhere. Term debt ₹2,000 Cr structured 80% due years 5–6. Net debt target ₹1,700 Cr by Mar 2027 (from ₹2,100 Cr Q1). Supply chain optimization critical. Margin expansion 250–400 bps on acquired business regardless.
Guidance
FY27 revenue growth: volume high single- to low double-digit, +300 bps revenue above volume
MediumFY27: Maintains prior volume guidance. Revenue uplift mechanism 300 bps above volume (mix, pricing). Specific quantified for first time.
FY28–FY29 mid-teens volume CAGR; revenue +300 bps above volume
MediumNew launches FY28 onwards unlock mid-double digit growth initially, escalating to mid-teens CAGR. Substantive upgrade vs prior 'low double-digit acceleration'.
FY27: Improve beyond Q4 FY26 baseline 15.5% EBITDA
MediumQ1 achieved 16.1% adjusted; management expects Q3/Q4 uptick seasonality + offset from A&SP spend. Q2 margin range similar.
FY29 EBITDA margin 16–18% (combined business) with upward bias
MediumStructured timeline upgrade vs prior vague '150–250 bps expansion 24–36 months'. Implies ~100–300 bps expansion from Q1 16.1% by FY29. Concrete but ambitious.
Acquired (IB) business margin expansion 250–400 bps irrespective of macro
MediumSynergies on supply chain, cost reduction expected 250–400 bps on Imperial Blue standalone by FY29, independent of inflation assumptions.
No specific capex quantum disclosed
LowFocus mentioned on efficient capital deployment and working capital investment. Net debt reduction ₹400 Cr FY27 implies capex discipline.
Risks the call surfaced
Profitability quality
HighPAT down 64% YoY to ₹31.6 Cr (NPM 1.4%) despite revenue +161%. Adjusted PAT ₹96 Cr (9.4%) masks ₹30 Cr exceptions & amortization. Gross margin fell 310 bps QoQ to 42.1%.
Integration execution
Medium90% of Imperial Blue integrated by April; 1 state remains under TSMA with March 2027 outer date. Disruptions in Odisha, Punjab, Uttarakhand, Karnataka attributed to TSMA (no detail given). Sales & manufacturing at scale in new geographies (North, East, West) only 7 months in.
Competitive intensity
MediumICONiQ White targeting 50% growth, McDowell's ramping scotch in segment; management sees long-dormant segment now active. Trade spend escalation risk. Large country liquor volume just below price point is buffer but no guarantee.
Debt & working capital
MediumNet debt ₹2,100 Cr Q1 (vs target ₹1,700 Cr March 2027). Gross debt ₹2,241 Cr. Increase due to full working capital cycle investment post-acquisition. Repayment structure front-loaded on term debt into years 5–6 provides buffer but elevation from legacy ₹700 Cr+ range.
Policy/regulatory
LowTelangana price increase 150–200 bps margin upside but not yet finalized (3 years since last increase; active discussions). Tamil Nadu market opening (50M+ brandy cases) speculative on new government policy; current TI presence <0.5M cases.
Management
Score 7/10. Clear, detailed on execution (integration timeline, team scaling, activation numbers). Transparent on challenges (inflation, competition, margin pressure). Conservative on granular state data (deferred) but candid on trends. NSR calculation change disclosed. Integration 90% complete <4 months (strong). Market share gains confirmed all regions. Volume growth 172% YoY delivered. BUT: PAT -64% YoY and profitability deteriorated despite revenue surge—execution on cost control/price mitigation lagging.
1 · Q2 FY27 (Aug–Sep 2026)
Telangana price increase negotiation outcome (150–200 bps margin upside if secured)
2 · Delhi relaunch (Jul 2026)
Imperial Blue targeting 0.5M case recovery within 12–18 months (pre-COVID peak)
3 · FY28 (Apr 2027+)
New product launches in vacant portfolio segments; mid-double digit volume growth unlocks
Forward EBITDA/volume guidance upgraded (mid-teens growth, 16–18% margins by FY29), but execution risk remains: inflation status-quo assumed, competitive intensity rising, margin recovery deferred to FY29.